Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference
January 11 2021 - 7:30AM
Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or
“the Company”), today announced that the Company is participating
in the H.C. Wainwright BioConnect 2021 Conference being held
virtually January 11-14, 2021. Conference specifics are as follows:
Event: |
H.C. Wainwright BioConnect 2021 Conference |
Date: |
January 11-14, 2021 |
Registration: |
https://hcwevents.com/bioconnect/ |
The recorded presentation can be accessed by conference
participants and the presentation deck can be accessed on the
investor relations section of the Diffusion Pharmaceuticals’
website.
About Diffusion Pharmaceuticals Inc.Diffusion
Pharmaceuticals Inc. is an innovative biopharmaceutical company
developing novel therapies that enhance the body’s ability to
deliver oxygen to the areas where it is needed most. Diffusion’s
lead product candidate, trans sodium crocetinate, is being
developed to enhance the diffusion of oxygen to tissues with low
oxygen levels, also known as hypoxia, a serious complication of
many of medicine’s most intractable and difficult-to-treat
conditions. In addition to TSC, our product candidate DFN-529, a
novel PI3K/Akt/mTOR pathway inhibitor, is in early-stage
development. We continue to explore alternatives regarding how best
to capitalize upon the value of DFN-529 and our associated
intellectual property. For more information, please visit us on the
web at www.diffusionpharma.com.
Forward-Looking StatementsThis press release
includes express and implied forward-looking statements. By their
nature, forward-looking statements involve risks and uncertainties
because they relate to and depend upon, among other things, events,
competitive dynamics, and industry change. The Company may, in some
cases, use terms such as “believes”, “estimates”, “anticipates”,
“expects”, “plans”, “intends”, “may”, “could”, “might”, “will”,
“should”, “approximately”, or other words that convey uncertainty
of future events or outcomes to identify these forward-looking
statements. Although the Company believes that it has a reasonable
basis for each forward-looking statement contained herein, as a
result of certain risks and uncertainties, known and unknown, the
Company’s actual results could differ materially from any
intentions, beliefs, projections, outlook, analyses, or
expectations expressed herein. Particular risk and uncertainties
include, among other things, those related to: the Company’s
ability to design, initiate, execute, and complete its ongoing and
planned studies evaluating TSC; the Company’s ability to achieve
its near-term strategic objectives, in the near-term or at all; the
Company’s ability to obtain additional financing; the success and
timing of the Company’s clinical trials and preclinical studies,
including its ability to enroll subjects in such trials and studies
at anticipated rates; the Company’s ability to develop and
commercialize TSC or any other product candidate; the ongoing
COVID-19 pandemic; general economic, political, business, industry,
and market conditions, including the recent United States (”U.S.”)
presidential election; and the other factors discussed under the
heading “Risk Factors” in the Company’s filings with the U.S.
Securities and Exchange Commission (“SEC”). Any forward-looking
statements in this press release speak only as of the date hereof
(or such earlier date as may be identified) and, except as required
by applicable law, rule, or regulation, the Company undertakes no
obligation to update any such statements after the date hereof.
Comparisons of current and any prior period results are not
intended to express any ongoing or future trends or indications of
future performance, unless explicitly expressed as such, and should
only be viewed as historical data. For all forward-looking
statements, the Company claims the protection of the safe harbor
for forward-looking statements contained in the Private Securities
Litigation reform Act of 1995.
Contacts
Investors:Tiberend Strategic Advisors,
Inc.Maureen McEnroe, CFA/Miriam Miller(212) 375-2664/ (212)
375-2694 mmcenroe@tiberend.com/mmiller@tiberend.com
Media:Jeffrey FreedmanRooney Partners (646)
432-0191jfreedman@rooneyco.com
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Sep 2023 to Sep 2024